Contrast-enhanced ultrasound as a problem-solving tool and irreversible electroporation for a perivascular/peribiliary segment IVs colorectal liver metastasis: a case report Authors: Mario Romeo, Paolo Vaia, Marcello Dallio, Carmine Napolitano, Fiammetta Di Nardo, Claudio Basile, Luigi Maria Vitale, Marco Niosi, Alessandro Federico Published: 2026 ABSTRACT AbstractInterventional ultrasound (IUS) supported by contrast-enhanced ultrasound (CEUS) enables accurate real-time characterization and image-guided treatment of focal liver lesions. In nonsurgical candidates with colorectal liver metastases (CRLM), irreversible electroporation (IRE) is an emerging nonthermal ablative option, particularly for lesions adjacent to major vascular or biliary structures. We report the case of a 52-year-old woman with locally advanced rectal adenocarcinoma and multiple hepatic cysts resulting in a complex multicystic liver architecture, who presented with a 20-mm indeterminate lesion in segment IVs, highly suspicious for metastatic disease. After systemic chemotherapy, radiotherapy, and surgical resection of the primary tumor, the lesion persisted and measured 17 mm on follow-up imaging, with inconclusive findings on conventional imaging. CEUS played a pivotal role in distinguishing treatment-related perfusion abnormalities from viable tumor, ultimately demonstrating rim arterial enhancement and rapid portal washout highly suggestive of persistent viable metastasis. Because of the lesion’s central location and proximity to the hepatic vein and adjacent biliary structures, surgical resection and thermal ablation were considered less suitable. Therefore, IRE was selected as the most appropriate percutaneous local treatment. The procedure was successfully performed under ultrasound guidance, with immediate CEUS confirmation of complete ablation. At the most recent imaging follow-up (October 2025, 6 months after treatment), no evidence of residual or recurrent liver disease was observed.Keywords: Interventional ultrasound, Liver metastasis, Irreversible electroporation, Contrast-enhanced ultrasound Background Interventional ultrasound (IUS) refers to the use of real-time ultrasonography to guide minimally invasive diagnostic and therapeutic procedures in various organs, with a continuously growing interest proposing several practical applications to the management of focal liver lesions [1]. In this scenario, contrast-enhanced ultrasound (CEUS) represents a crucial IUS-supporting tool in hepatologic practice, often constituting a watershed in the diagnostic work-up, as well as a valuable method guiding the proper management of patients with primary and secondary hepatobiliary lesions [1]. In this way, in routine clinical practice, interventional radiologists are able to directly visualize target structures, precisely advance needles or devices, and continuously monitor the procedure, thereby enhancing accuracy and safety [1]. Combining radiologic expertise with real-time ultrasound and CEUS guidance enables efficient performance of liver biopsies, drainages, ablations, targeted injections, and other image-guided interventions, significantly reducing complication rates [1]. In the panorama of focal liver lesions, liver metastases constitute a major cause of death, dramatically burdening the prognosis of patients with various extra-gastrointestinal (including melanoma, breast cancer, lung tumors), and, predominantly, gastrointestinal-related primary cancers [2]. In patients with colorectal cancer (CRC), the hepatic parenchyma represents the most frequent site of secondary localizations. Surgical resection of oligo-colorectal liver metastases (CRLM), potentially combined with modern chemotherapy and biologic therapies, can improve the 5-year median survival rate to over 50% [2,3]. Anyway, the majority of patients (70%-80%) are not eligible for surgical resection due to factors such as comorbid conditions, extrahepatic disease, or unfavorable characteristics of the metastases, including their size, number, or location [2]. In the last decades, several minimally invasive techniques of IUS have emerged as viable alternatives for the local treatment of hepatic metastases [1]. Among these options, thermal ablation methods such as radiofrequency ablation (RFA) and microwave ablation (MA) have gained widespread use. These techniques rely on heat-based energy to induce coagulative necrosis within the tumor, offering effective local control with relatively low morbidity [4]. More recently, irreversible electroporation (IRE) has emerged as a promising nonthermal modality. IRE uses short, high-voltage electrical pulses to create permanent nanopores in the cell membrane, leading to apoptosis without damaging the extracellular matrix [5]. This technique is especially advantageous for tumors situated close to vessels or bile ducts, where thermal methods may pose a higher risk of collateral damage [2,4,5]. This case report highlights the importance of IUS in the diagnostic work-up and the relevance of the IRE as a modern emerging IUS-related technique in the management of patients not fit for surgery, presenting without other therapeutic options. Case report Events preceding the admission A 52-year-old female with a history limited to arterial hypertension and supraventricular tachyarrhythmias underwent colonoscopy in April 2022 for nonspecific gastrointestinal symptoms. The exam revealed a large ulcerated, bowl-shaped neoplastic lesion in the mid-rectum, approximately 8 cm in length, highly suspicious for malignancy. Multiple biopsies confirmed a moderately differentiated colorectal adenocarcinoma with a KRAS G12D mutation and no microsatellite instability, a profile relevant for subsequent therapeutic decisions. At initial staging in April 2022, contrast-enhanced computed tomography (CT) and Magnetic Resonance Imaging (MRI) revealed numerous benign-appearing hepatic cysts, some large, with the largest measuring 13 cm in the left lobe, resulting in a complex multicystic liver architecture. This background markedly complicated lesion detection and characterization, as the distorted hepatic anatomy and heterogeneous parenchymal appearance reduced the conspicuity of small focal lesions on conventional imaging. In this setting, a poorly enhancing 20-mm nodular lesion with ill-defined margins was identified in segment IVs, in proximity to the hepatic vein and biliary tract, raising suspicion for metastasis and further supported by Positron Emission Tomography (PET) uptake. Pelvic MRI showed transmural rectal wall infiltration with mesorectal fat extension, consistent with locally advanced disease (cT3N0M1a, according to the American Joint Committee on Cancer -AJCC- staging system) [6]. Given the advanced stage, systemic chemotherapy with Folinic Acid-Fluorouracil-Oxaliplatin-Irinotecan (FOLFOXIRI) regimen plus Bevacizumab was started in June 2022. Thirteen cycles were completed by December 2022, with partial response and tumor downstaging. In February 2023, the patient received short-course rectal radiotherapy followed by low anterior resection with protective ileostomy. Histology showed a local down-staging of the primary tumor (ypT2N0) with clear margins (R0), ultimately indicating a good response to neoadjuvant treatment. Following systemic treatment, postoperative cross-sectional imaging in 2023 revealed a secondary pulmonary lesion (in the left lower lobe), demonstrating persistence of the same hepatic segment IVs lesion, measuring 17 mm. The lesion showed atypical contrast behavior, raising doubts about its nature and viability. Therefore, to further assess and characterize the lesion, in July 2023, CEUS was performed. CEUS was executed using a GE LOGIQ E10 ultrasound platform with a contrast-specific low-mechanical-index technique after intravenous bolus injection of 2.4 mL sulfur hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy), followed by a 10-mL saline flush. Dynamic enhancement was continuously assessed in real time during the arterial (10-30 seconds), portal venous (31-120 seconds), and late (>120 seconds) phases. Split-screen display with simultaneous B-mode and contrast imaging was used when appropriate to optimize lesion localization and interpretation [7]. The lesion showed faint, progressive arterial phase enhancement, without definite washout in the portal or late phases, becoming iso-enhancing relative to the surrounding liver parenchyma in the late phase. This vascular pattern was considered nonspecific and interpreted as more suggestive of altered perfusion related to chemotherapy-induced hepatic injury or a partially regressed oligometastasis rather than unequivocal viable disease. The examination proved particularly valuable because of its real-time assessment of lesional microvascular perfusion. Despite further systemic therapy with the De Gramont scheme plus Bevacizumab and then FOLFIRI plus Bevacizumab, the hepatic lesion remained stable but suspicious. In December 2023, stereotactic body radiotherapy was delivered to the left lower lobe pulmonary lesion (50 Gray in 5 fractions) with good local control. Maintenance therapy with the De Gramont scheme and Bevacizumab continued for 12 months. On 12-month follow-up, imaging on January 25 suggested oligoprogression involving the liver. Table 1 and Figure 1 report the chronology of the events. Table 1Clinical timeline: treatments and imaging findings from 2022 to 2025.Table 1 dummy alt textDateClinical step/treatmentImaging findingsApril 2022Initial staging for rectal adenocarcinomaCT/MRI: multiple benign-appearing hepatic cysts; 20-mm lesion in segment IVs suspicious for metastasis; PET uptake positive2022Neoadjuvant systemic chemotherapy and radiotherapyInterval treatment response assessment performedLate 2022/Early 2023Surgical resection of primary rectal tumorNo immediate local pelvic recurrence reportedJuly 2023CEUS evaluation of hepatic lesionFaint progressive arterial enhancement, no definite washout, late iso-enhancement; interpreted as treatment-related perfusion change or partially regressed oligometastasis2023Postoperative follow-up imagingPersistent segment IVs lesion measuring 17 mm with inconclusive conventional imaging featuresFebruary 2025Referral for interventional ultrasound reassessmentB-mode US: ∼10-mm iso-echoic lesion in segment IVsFebruary 2025Repeat CEUSPeripheral rim arterial hyperenhancement with rapid portal washout, consistent with viable metastasisApril 2025Percutaneous IRE treatmentImmediate CEUS: nonenhancing ablation zone, no residual enhancementOctober 20256-month imaging follow-upPersistent nonenhancing ablation zone without arterial hyperenhancement or washout; no evidence of residual/recurrent diseaseCT, computed tomography; CEUS, contrast-enhanced ultrasound; IRE, irreversible electroporation; MRI, magnetic resonance imaging; PET, positron emission tomography; US, ultrasound. Clinical timeline: treatments and imaging findings from 2022 to 2025. CT, computed tomography; CEUS, contrast-enhanced ultrasound; IRE, irreversible electroporation; MRI, magnetic resonance imaging; PET, positron emission tomography; US, ultrasound. Timeline of the events. CRC, colorectal cancer; Dec, December; Feb, February; CEUS, contrast-enhanced ultrasound; FOLFIRI, folinic acid-fluorouracil-oxaliplatin-irinotecan; IRE, irreversible electroporation. Admission to the hepatogastroenterology unit At repeat ultrasound assessment in February 2025, the lesion appeared as an approximately 10-mm iso-echoic nodule on B-mode imaging in segment IVs (Fig. 2). The smaller size on ultrasound likely reflected differences in modality resolution, imaging plane, and visualization of only the viable sonographically detectable component. At repeat CEUS assessment in February 2025, performed by using the same above-reported protocol, the lesion demonstrated a more convincing malignant vascular pattern, characterized by peripheral rim arterial phase hyperenhancement followed by rapid washout in the portal venous phase [arterial phase assessment (10-30 seconds) demonstrated peripheral enhancement, with subsequent portal venous phase washout (31-120 seconds)]. Compared with the prior examination, the newly evident washout and more conspicuous rim enhancement strongly supported the imaging diagnosis of persistent viable metastatic disease, although no histopathological confirmation was obtained. Baseline B-mode ultrasound and CEUS evaluation of the segment IV lesion. The lesion appears as an approximately 10-mm iso-echoic nodule on B-mode imaging. Given the lesion’s isolated nature and the absence of widespread hepatic involvement, the case was re-evaluated for local ablative therapy. In March 2025, the interventional multidisciplinary team (including oncologists, surgeons, radiologists, and hepatologists) confirmed that the lesion was technically amenable to percutaneous local treatment. At the time of multidisciplinary reassessment, the patient showed preserved liver function, with normal bilirubin (0.7 mg/dL) and no clinically relevant abnormalities in transaminases or signs of cholestasis. Serum carcinoembryonic antigen (CEA) was low and stable (3.1 ng/mL) compared with previous assessments. The previously treated pulmonary lesion remained locally controlled after stereotactic body radiotherapy, and no new extrahepatic metastatic disease was detected on restaging imaging. Overall, the disease burden was therefore consistent with an oligometastatic setting potentially amenable to focal local therapy. Moreover, the rationale for treatment selection was discussed within the multidisciplinary team. Surgical resection was considered technically possible but relatively invasive for a small, centrally located segment IVs lesion in a patient who had already undergone multimodal treatment. Thermal ablation techniques were considered less suitable because of the lesion’s proximity to the hepatic vein and biliary structures, with potential risk of heat-sink effect, incomplete margins, or collateral biliary injury. Additional stereotactic radiotherapy was also considered less attractive, given prior thoracic Stereotactic Body Radiotherapy (SBRT) and the availability of a percutaneous tissue-sparing ablative option. On this basis, IRE was selected as the most appropriate local treatment. Considering this, following the multidisciplinary team decision, in April 2025, the patient underwent an electroporation procedure. IRE was performed using the Dophi™ N3000 electroporation platform (Surgnova Healthcare Technologies, Zhejiang, China). Under general anesthesia and with real-time ultrasound navigation, three 19-gauge monopolar electrodes were inserted percutaneously in a parallel configuration around the target lesion, including 1 trigger probe and 2 standard probes. This configuration was selected to ensure adequate coverage of the approximately 20-mm spherical segment IVs lesion while minimizing the risk of injury to the adjacent hepatic vein and biliary structures. Inter-electrode spacing and active tip exposure (adjustable from 0 to 4 cm) were selected according to lesion dimensions to obtain complete target coverage with an intended circumferential safety margin of approximately 5-10 mm. Pulse delivery was performed using the manufacturer’s preset IRE protocol with high-voltage pulses (within the system operating range of 500-3000 V), with final voltage and number of pulses adapted intra-procedurally according to current feedback and tissue impedance. ECG synchronization was used when required, and real-time monitoring of voltage, current, impedance, waveform delivery, and probe temperature was continuously performed throughout the procedure. Immediate postprocedural CEUS confirmed complete ablation (Fig. 3). Complete ablation was defined as the absence of any residual intralesional arterial enhancement and the absence of washout-compatible viable tissue within or at the margin of the treated zone. The patient tolerated the procedure without complications and was discharged a few days later in stable condition. Immediate postprocedural CEUS after irreversible electroporation. During arterial, portal venous, and late phases (T1: 3 minutes and 31 seconds), the treated area (arrow) remained completely avascular, with no residual contrast enhancement, confirming complete ablation. Follow-up CEUS performed 6 months after IRE (October 2025) demonstrated a persistent nonenhancing ablation zone, with no focal arterial phase hyperenhancement and no late washout, indicating no evidence of residual or recurrent viable disease (Fig. 4) with the patient remaining on maintenance systemic therapy. Follow-up CEUS (six months after irreversible electroporation). Dynamic evaluation through the arterial, portal venous, and late phases (T1: 3 minutes and 31 seconds) demonstrated a persistent nonenhancing ablation zone in the previously treated area (box), without focal arterial hyperenhancement or subsequent washout suspicious for residual or recurrent tumor. Discussion This case highlights 2 clinically relevant aspects of multidisciplinary management of CRLM: the role of serial CEUS in resolving an equivocal post-treatment lesion, and the use of IRE as a safe local treatment for a metastasis located close to critical vascular and biliary structures [1]. First, the case illustrates the difficulty of characterizing small or atypical liver lesions in patients undergoing systemic therapy, particularly in a complex hepatic background altered by multiple cysts. In this regard, the presence of multiple hepatic cysts represented an additional diagnostic challenge, as altered liver morphology and heterogeneous parenchymal background may reduce the conspicuity of small focal lesions and limit confident characterization on conventional imaging. In this context, CEUS proved essential, representing the IUS-supporting tool propaedeutic to further approaches. By enabling real-time assessment of microvascular perfusion, high temporal resolution, and repeatability, CEUS allowed differentiation between therapy-related perfusional changes and persistent viable tumor. An important teaching point from this case is the dynamic interpretation of CEUS findings over time. In 2023, the absence of definite washout and the progressive mild enhancement pattern favored post-treatment perfusional changes or partial response. In contrast, the 2025 examination showed rim arterial hyperenhancement with rapid washout, a pattern much more typical of viable CRLM. The evolution from a pattern compatible with altered perfusion to 1 demonstrating rapid washout ultimately supported the diagnosis of a viable metastasis, guiding subsequent therapeutic decisions [7]. Serial CEUS, therefore, provided clinically meaningful functional information beyond morphology alone. A pathological confirmation of the hepatic lesion was not obtained, and the diagnosis was therefore based on multidisciplinary clinic-radiological assessment rather than tissue sampling. However, the pretest probability of metastasis was high, given the known colorectal primary tumor, initial PET uptake, persistence of the lesion despite treatment, and the interval development of a malignant CEUS pattern characterized by rim arterial hyperenhancement and rapid washout. The absence of suspicious enhancement after IRE and the stable follow-up findings further supported the working diagnosis, although they cannot replace histological proof. Second, the case highlights the importance of selecting local therapy according to lesion location. Although systemic disease control had been achieved, the hepatic lesion in segment IVs remained biologically active and potentially amenable to local treatment. Because the lesion was adjacent to the hepatic vein and biliary structures, surgical resection would have been more invasive, and thermal ablation potentially less suitable because of collateral injury risk. IRE was therefore selected because its nonthermal mechanism allows treatment while better preserving nearby vessels and bile ducts [5,[8], [9], [10]]. Immediate CEUS demonstrated a nonenhancing ablation zone, and follow-up imaging showed no evidence of residual or recurrent viable disease, supporting the feasibility and effectiveness of this approach in carefully selected patients. Anyway, these findings should be interpreted in light of the limitations of a single case report. Histopathological confirmation of residual viable tumor was not available because no preablation biopsy was performed, follow-up duration remains limited, and treatment selection was inherently influenced by multidisciplinary case-specific judgment. Therefore, the present report should be considered hypothesis-generating and illustrative of a possible management strategy rather than evidence of superiority over other local treatment options. Conclusion In conclusion, in the era of Precision Medicine, the presented case suggests that in selected patients with technically challenging CRLM, serial CEUS may provide useful functional information when conventional imaging is inconclusive, and IRE may represent a feasible nonthermal local treatment option near critical vascular or biliary structures. These observations require confirmation in larger studies. Author contributions P.V., M.R., and M.D.: guarantor of the article, conceptualization, methodology, investigation, and writing the original draft; C.N., F.D.N., and C.B.: conceptualization, methodology, formal analysis, investigation, and writing the original draft. L.M.V., M.N., A.F.: conceptualization, data curation, supervision. All authors approved the final version of the manuscript. Informed consent Informed consent was obtained from the participant included in the study. Consent to publish The authors affirm that human research participants provided informed consent for publication of the images in Figures 2, 3, and 4. Patient consent The patient consent has been obtained from the patient for publication of this case report. Footnotes Competing Interests: The authors have declared that no competing interests exist. Acknowledgments: This research received no financial support. Figure 1 was created using the graphical software Biorender.com (https://app.biorender.com/). References